Cure8 research brief
This study addresses whether continuing advanced biologic therapies around abdominal surgery raises short-term postoperative risks—important for IBD patients and clinicians planning surgery.
It also highlights higher infection and sepsis associations with immunomodulators and corticosteroids, which can influence perioperative medication strategies.
Patients with Crohn’s disease or ulcerative colitis preparing for surgery, caregivers, IBD gastroenterologists, and colorectal surgeons.
This PubMed abstract reports a retrospective cohort study of 274 adults with chart-confirmed IBD who underwent index IBD-related abdominal surgery between 2010 and 2024.
The investigators compared 30-day postoperative outcomes (infection, sepsis, reoperation, readmission, and length of stay) by perioperative exposure to biologic/advanced therapies, corticosteroids, and immunomodulators.
The study found that perioperative exposure to biologic/advanced therapies (including anti-TNFs, anti-integrins, and IL-12/23 or IL-23 inhibitors) was not associated with increased composite 30-day postoperative complications and was associated with a slightly shorter postoperative length of stay.
By contrast, perioperative immunomodulators were linked to higher odds of intra-abdominal and urinary tract infections, and corticosteroid exposure was associated with higher odds of sepsis.
These findings support continuing biologic/advanced therapies around the time of surgery when clinically indicated, while reinforcing the risks associated with perioperative corticosteroid use and some immunomodulators. Decisions should be individualized within a multidisciplinary surgical and IBD care team.
Retrospective single-center design limits causal inference and may include selection or confounding biases. Exposure definitions and adjustment variables are described in the abstract; consult the full article for detailed methods and subgroup analyses.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Competing interests: None to report by all authors. Consent for publication: Not applicable.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and...
Reducing long-term corticosteroid use matters because steroids have significant side effects when used repeatedly or chronically. The study suggests ileocaecal resection may lower steroid exposure for many patients, but...
This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...
